Aqualab, the Direct-to-Retail division of Laborate Pharmaceuticals India Ltd, has crossed the ₹100 crore revenue mark within three years of launch and now expects to touch ₹250 crore by FY 25–26. The growth has been driven by an expanding portfolio of over 800 SKUs and a network of 500+ retail stockists, with Tier-II and Tier-III markets contributing a rising share of sales.
Since its inception in 2022, the division has reported consistent year-on-year growth, moving from ₹76 crore in FY 2022–23 to ₹108 crore in FY 2023–24, Aqualab has focused on ensuring affordability and last-mile access, enabling its medicines to reach smaller towns alongside metropolitan centres.
“Crossing ₹100 crore in three years demonstrates how quickly the Direct-to-Retail model is scaling in India. We are now targeting ₹250 crore by FY 25–26, with non-metro markets expected to contribute 42% of incremental growth. Expanding therapeutic categories and strengthening last-mile delivery will remain our key focus areas,” said Arpit Bhatia, Managing Director, Laborate Pharmaceuticals.
Aqualab’s rise is in step with national priorities such as Make in India and the government’s PLI push to boost domestic pharma manufacturing. The retail pharmacy market, pegged at ₹18,700 crore in FY24, is projected to touch ₹31,200 crore by FY32, growing at a CAGR of 6.6% on the back of stronger generic penetration, greater health awareness, and organised distribution. Leveraging this momentum, Aqualab is preparing to expand into new categories, add facilities, adopt digital channels, and explore exports, consolidating its position in India’s retail pharma landscape.
Laborate’s WHO, GMP, and EU GMP-certified facilities have provided Aqualab with the infrastructure to scale rapidly while maintaining international quality standards. The company operates modern plants with advanced manufacturing and quality control systems, enabling compliance with stringent benchmarks. This foundation has not only supported Aqualab’s domestic expansion but also positions the division for potential export opportunities in the future.
About Laborate Pharmaceuticals
Founded in 1985, Laborate Pharmaceuticals is one of the leading pharmaceutical companies in India, with capabilities in manufacturing, R&D, and global distribution. The company provides pharmaceutical products in therapeutic categories that include CVS, Diabetics, Pain Management, CNS, and other general categories, and has presence in 55 countries worldwide.
Laborate’s facilities are cGMP compliant with several regulatory agencies including WHO-GMP, and now EU-GMP compliance. With innovation, quality, and affordability as the cornerstones of its strategy, Laborate is able to provide drugs in both branded and contract manufacturing capacities, to its clients.
Also Read: How Kiwi Is Disrupting the Credit Card Market with UPI?
